BACKGROUND: The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. METHODS: We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2.5 mg/kg), and linezolid (100 mg/kg) (BDL) on the mycobacterial load in the lungs and spleen of tuberculosis-infected mice during a treatment period of 24 weeks. This treatment was compared with the standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). Relapse was assessed 12 weeks after treatment. Two logistic regression models were developed to compare the efficacy of both regimens. RESULTS: Culture negativity in the lungs was achieved at 8 and 20 weeks of treatment with BDL and HRZE, respectively. After 14 weeks of treatment only 1 mouse had relapse in the BDL group, while in the HRZE group relapse was still observed at 24 weeks of treatment. Predictions from the final mathematical models showed that a 95% cure rate was reached after 20.5 and 28.5 weeks of treatment with BDL and HRZE, respectively. CONCLUSION: The BDL regimen was observed to be more effective than HRZE and could be a valuable option for the treatment of DR tuberculosis.
BACKGROUND: The treatment success rate of drug-resistant (DR) tuberculosis is alarmingly low. Therefore, more effective and less complex regimens are urgently required. METHODS: We compared the efficacy of an all oral DR tuberculosis drug regimen consisting of bedaquiline (25 mg/kg), delamanid (2.5 mg/kg), and linezolid (100 mg/kg) (BDL) on the mycobacterial load in the lungs and spleen of tuberculosis-infected mice during a treatment period of 24 weeks. This treatment was compared with the standard regimen of isoniazid, rifampicin, pyrazinamide, and ethambutol (HRZE). Relapse was assessed 12 weeks after treatment. Two logistic regression models were developed to compare the efficacy of both regimens. RESULTS: Culture negativity in the lungs was achieved at 8 and 20 weeks of treatment with BDL and HRZE, respectively. After 14 weeks of treatment only 1 mouse had relapse in the BDL group, while in the HRZE group relapse was still observed at 24 weeks of treatment. Predictions from the final mathematical models showed that a 95% cure rate was reached after 20.5 and 28.5 weeks of treatment with BDL and HRZE, respectively. CONCLUSION: The BDL regimen was observed to be more effective than HRZE and could be a valuable option for the treatment of DR tuberculosis.
Authors: Koen Andries; Peter Verhasselt; Jerome Guillemont; Hinrich W H Göhlmann; Jean-Marc Neefs; Hans Winkler; Jef Van Gestel; Philip Timmerman; Min Zhu; Ennis Lee; Peter Williams; Didier de Chaffoy; Emma Huitric; Sven Hoffner; Emmanuelle Cambau; Chantal Truffot-Pernot; Nacer Lounis; Vincent Jarlier Journal: Science Date: 2004-12-09 Impact factor: 47.728
Authors: Jurriaan E M de Steenwinkel; Marian T ten Kate; Gerjo J de Knegt; Henri A Verbrugh; Rob E Aarnoutse; Martin J Boeree; Michael A den Bakker; Dick van Soolingen; Irma A J M Bakker-Woudenberg Journal: Antimicrob Agents Chemother Date: 2012-07-16 Impact factor: 5.191
Authors: J E M De Steenwinkel; G J De Knegt; M T Ten Kate; A Van Belkum; H A Verbrugh; R Hernandez-Pando; D Van Soolingen; I A J M Bakker-Woudenberg Journal: Int J Immunopathol Pharmacol Date: 2009 Jul-Sep Impact factor: 3.219
Authors: Jian Xu; Si-Yang Li; Deepak V Almeida; Rokeya Tasneen; Kala Barnes-Boyle; Paul J Converse; Anna M Upton; Khisimuzi Mdluli; Nader Fotouhi; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Brendon M Lee; Liam K Harold; Deepak V Almeida; Livnat Afriat-Jurnou; Htin Lin Aung; Brian M Forde; Kiel Hards; Sacha J Pidot; F Hafna Ahmed; A Elaaf Mohamed; Matthew C Taylor; Nicholas P West; Timothy P Stinear; Chris Greening; Scott A Beatson; Eric L Nuermberger; Gregory M Cook; Colin J Jackson Journal: PLoS Pathog Date: 2020-02-07 Impact factor: 6.823
Authors: Rokeya Tasneen; Andrew Garcia; Paul J Converse; Matthew D Zimmerman; Veronique Dartois; Ekaterina Kurbatova; Andrew A Vernon; Wendy Carr; Jason E Stout; Kelly E Dooley; Eric L Nuermberger Journal: Antimicrob Agents Chemother Date: 2022-03-22 Impact factor: 5.938
Authors: Saskia E Mudde; Anna M Upton; Anne Lenaerts; Hannelore I Bax; Jurriaan E M De Steenwinkel Journal: J Antimicrob Chemother Date: 2022-03-31 Impact factor: 5.790
Authors: Saskia E Mudde; Rami Ayoun Alsoud; Aart van der Meijden; Anna M Upton; Manisha U Lotlikar; Ulrika S H Simonsson; Hannelore I Bax; Jurriaan E M de Steenwinkel Journal: J Infect Dis Date: 2022-06-01 Impact factor: 7.759